Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Emicizumab in acquired hemophilia A
2019-004430-42Phase 2Completed
- Sponsor
- GWT-TUD
- Start
- Nov 2020
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of emicizumab in acquired haemophilia (AH), sponsored by GWT-TUD. Primary endpoint: Rate of clinically significant bleeds per patient-week. Started Nov 2020; status: completed.
02
Drugs
emicizumab
03
Conditions
acquired haemophilia (AH)
Beyond the preview
Go deeper on 2019-004430-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004430-42.